×

Baron Philippe Vlerick increases shareholding in ThromboGenics NV to 6.4%

Regulated Information - Transparency Statement

LEUVEN, Belgium, Sept. 10, 2015 (GLOBE NEWSWIRE) -- Pursuant to Belgian transparency legislation (Law of 2 May 2007), ThromboGenics NV (Euronext Brussels: THR) received a transparency notification on 9 September 2015 from Philippe Vlerick and controlled entities.

Philippe Vlerick (Bareldam SA) notified that on 9 September 2015, 2,324,719 shares, representing 6.44% of the current 36,094,349 outstanding ThromboGenics shares, were held by himself and controlled entities.

On September 9, 2015, based on all received transparency declarations received, ThromboGenics NV is aware of the following participations:

Shareholder number of securities % of voting rights
Mr Landon T. Clay and all entities controlled by him

1,071,061


2.97%
Mr Thomas M. Clay and all entities controlled by him

2,790,062


7.73%
Norges Bank 1,065,605 2.95%
Philippe Vlerick and all entities controlled by him 2,324,719 6.44%

In May, Baron Philippe Vlerick was appointed as a non-executive member of the Board of ThromboGenics NV at an extraordinary shareholders' assembly that took place on August 20th.

Philippe Vlerick is the owner, Chairman and CEO of several businesses in Belgium and abroad. He currently serves as the Chairman and Chief Executive Officer of Vlerick Group (Belgium). He also serves as the Chairman and CEO of UCO Textiles NV. In addition, he is the Vice-chairman of KBC Group, Corelio, smartphoto Group and Durabilis. Baron Vlerick is also a member of the Board of Directors of Exmar, Hamon & Cie, Besix Group and I.V.C. (Belgium).

Mr Vlerick holds a Degree in Philosophy and Law from the University of Leuven, and an MBA General Management degree (PUB) (Ghent, Vlerick School of Management - 1979). He also holds a Master's degree in Business Administration from Indiana University, Bloomington (USA - 1980).

He was elected 2006 Manager of the Year by Trends, a leading business magazine in Belgium. He was granted the title of Baron in 2008, and became Commander of the Order of Leopold in 2013.

END

For further information please contact:

ThromboGenics



Wouter Piepers,

Global Head of Corporate Communications & IR

+32 16 75 13 10 / +32 478 33 56 32

wouter.piepers@thrombogenics.com

Citigate Dewe Rogerson



David Dible/Malcolm Robertson

Tel: +44 20 7282 2867

Malcolm.robertson@citigatedr.co.uk

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease.

The Company's first product, JETREA® (ocriplasmin), has been approved in 53 countries across the globe. In the US, ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics inc. ThromboGenics signed an agreement with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States.

ThromboGenics is planning a Phase II clinical trial with JETREA® in diabetic retinopathy. Next to JETREA®, the company is in the midst of evaluating a number of potential candidates for next generation treatments in diabetic eye disease.

ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

HUG#1951178

Source:ThromboGenics NV